Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A 4-Year, Open-Label, Multicenter, Randomized Trial of Genotropin® Growth Hormone in Patients with Idiopathic Short Stature: Analysis of 4-Year Data Comparing Efficacy, Efficiency, and Safety between an Individualized, Target-Driven Regimen and Standard Dosing.

Counts DR, Silverman LA, Rajicic N, Geffner ME, Newfield RS, Thornton P, Carakushansky M, Escobar O, Rapaport R, Levitsky L, Rotenstein D, Hey-Hadavi J, Wajnrajch MP. A 4-Year, Open-Label, Multicenter, Randomized Trial of Genotropin® Growth Hormone in Patients with Idiopathic Short Stature: Analysis of 4-Year Data Comparing Efficacy, Efficiency, and Safety between an Individualized, Target-Driven Regimen and Standard Dosing. Horm Res Paediatr. 2015; 84(2):79-87.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.